LMR Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

LMR Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-863,134	Closed	-$114M	–	1739
2025 Q1	$114M	Buy	863,134 +854,957	+10,456%	+$107M	1.07%	9
2024 Q4	$683K	Sell	8,177 -23,000	-74%	-$1.89M	0.01%	783
2024 Q3	$2.28M	Sell	31,177 -2,112	-6%	-$159K	0.02%	569
2024 Q2	$2.28M	Buy	33,289 +12,329	+59%	+$855K	0.02%	519
2024 Q1	$1.45M	Buy	+20,960	New	+$1.44M	0.01%	614
2023 Q4	–	Sell	-4,700	Closed	-$270K	–	1162
2023 Q3	$245K	Buy	+4,700	New	+$274K	﹤0.01%	620
2022 Q4	–	Sell	-7,900	Closed	-$368K	–	1309
2022 Q3	$368K	Hold	7,900	–	–	0.01%	933
2022 Q2	$451K	Sell	7,900 -7,500	-49%	-$425K	0.01%	949
2022 Q1	$942K	Buy	+15,400	New	+$800K	0.01%	848
2021 Q4	–	Sell	-12,000	Closed	-$447K	–	1306
2021 Q3	$447K	Buy	+12,000	New	+$417K	0.01%	821
2020 Q2	–	Sell	-50,000	Closed	-$791K	–	651
2020 Q1	$791K	Sell	50,000 -50,000	-50%	-$1.09M	0.04%	143
2019 Q4	$3.43M	Buy	+100,000	New	+$1.2M	0.01%	97

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

LMR Partners's ITCI Position: Q2 2025 in Review

LMR Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 863,134 shares — an estimated $114M sold.

LMR Partners first reported a position in ITCI in Q4 2019 and held it in 12 quarters. The position peaked at $114M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

LMR Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
LMR Partners sold 863,134 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $114M.
LMR Partners first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 12 quarters.
LMR Partners's Intra-Cellular Therapies Inc. position peaked at $114M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.